March 20, 2024
SGLT2i, GLP-1 RA Prescribing Lower for Minority Patients
Second study shows low rate of SGLT2i prescribing even among patients with indications for therapy Pharmacy dispensing patterns for sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide 1 receptor agonist (GLP1-RA) medications show lower prescribing for minority patients; and the rate of SGLT2i prescriptions is low among patients with indications for therapy, according to two...
COVID-19 Viral Load Rebound Can Occur After VV116, Nirmatrelvir-Ritonavir
Viral load rebound, symptom rebound common with VV116, nirmatrelvir-ritonavir in mild-to-moderate COVID-19 For patients with mild-to-moderate COVID-19, viral load rebound and symptom rebound can occur after a standard five-day course of treatment with VV116 or nirmatrelvir-ritonavir, according to a study published online March 13 in JAMA Network Open. Zhitao Yang, M.D., from Ruijin Hospital in Shanghai,...
Second Primary Malignancies Represent Small Proportion of Adverse Events After CAR T-Cell Therapy
Most reports of SPMs included axicabtagene ciloleucel and tisagenlecleucel; most frequent SPMs were leukemias Second primary malignancies (SPMs) represent a small proportion of adverse events (AEs) reported by patients receiving chimeric antigen receptor T-cell (CAR T-cell) therapy, according to a letter to the editor published online March 14 in Blood. Noting that CAR T-cell-eligible patients are...